uploads/2018/02/Chart-03-3-1.jpg

A Look at Sanofi Genzyme in 4Q17

By

Updated

Sanofi Genzyme

Sanofi Genzyme includes Sanofi’s (SNY) specialty care products. Sanofi Genzyme reported revenues of ~1.5 billion euros in 4Q17 for 16.8% growth in operating revenues compared to 4Q16, excluding the revenues from emerging markets.

The chart above compares the revenues for Sanofi Genzyme since 1Q16. When including the revenues from emerging markets, Sanofi Genzyme’s revenues totaled 1.7 billion euros in 4Q17 for 16.5% growth compared to 4Q16.

Article continues below advertisement

Sanofi Genzyme portfolio

Sanofi Genzyme includes specialty products like immunology drugs, multiple sclerosis drugs, oncology drugs, and rare diseases drugs. The growth in Sanofi Genzyme’s 4Q17 revenues was driven by strong sales of Dupizent from the immunology portfolio; Aubagio from the multiple sclerosis portfolio; Jevtana, Mozobil, and Zaltrap from the oncology portfolio; and Cerezyme, Cerdelga, Aldurazyme, Fabrazyme, and Myozyme from the rare diseases portfolio.

Immunology portfolio

Sanofi’s (SNY) immunology portfolio comprises two drugs: Dupixent and Kevraza. These drugs reported revenues of 126.0 million euros in 4Q17, driven by the strong sales of Dupixent in the US markets of 116.0 million euros.

Article continues below advertisement

Multiple sclerosis portfolio

Sanofi’s multiple sclerosis portfolio comprises two drugs: Aubagio and Lemtrada. These drugs reported revenues of 501.0 million euros in 4Q17, reflecting 10.5% growth in operating revenues, including the revenues from emerging markets. 

Excluding the revenues from emerging markets, the multiple sclerosis portfolio reported revenues of 484.0 million euros in 4Q17, reflecting 10.0% growth in operating revenues in 4Q17. 

Other drugs for the treatment of multiple sclerosis include Teva Pharmaceuticals’ (TEVA) Copaxone, Biogen’s (BIIB) Tysabri and Tecfidera, and Novartis’s (NVS) Gilenya.

Oncology portfolio

Sanofi’s oncology products portfolio includes Jevtana, Mozobil, Eloxatine, Taxotere, Zaltrap, and Thymoglobulin. The oncology portfolio reported revenues of 361.0 million euros in 4Q17 for 3.5% growth in operating revenues, including revenues from emerging markets. 

Excluding the revenues from emerging markets, the portfolio’s revenues totaled 259.0 million euros in 4Q17, an ~1.1% decline compared to 4Q16. This trend was driven by slower sales of Taxotere and Eloxatine, and it was substantially offset by strong sales of Jevtana, Thymoglobulin, and Zaltrap.

Rare diseases portfolio

Sanofi’s (SNY) rare diseases portfolio includes Aldurazyme, Cerezyme, Myozyme, Febrazyme, and Cerdelga. The rare diseases portfolio reported revenues of 726.0 million euros for 8.0% growth in operating revenues, including the revenues from emerging markets. 

Excluding the revenues from emerging markets, the rare disease portfolio reported revenues of 597.0 million euros in 4Q17, driven by strong sales of all products.

Advertisement

More From Market Realist